HUP0100597A2 - Hidroxámsav- és karbonsavszármazékok - Google Patents

Hidroxámsav- és karbonsavszármazékok

Info

Publication number
HUP0100597A2
HUP0100597A2 HU0100597A HUP0100597A HUP0100597A2 HU P0100597 A2 HUP0100597 A2 HU P0100597A2 HU 0100597 A HU0100597 A HU 0100597A HU P0100597 A HUP0100597 A HU P0100597A HU P0100597 A2 HUP0100597 A2 HU P0100597A2
Authority
HU
Hungary
Prior art keywords
alkyl
group
heteroaryl
aryl
heterocycloalkyl
Prior art date
Application number
HU0100597A
Other languages
English (en)
Inventor
Andrew Douglas Baxter
John Gary Montana
David Alan Owen
Original Assignee
Darwin Discovery Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802073.8A external-priority patent/GB9802073D0/en
Priority claimed from GBGB9819574.6A external-priority patent/GB9819574D0/en
Application filed by Darwin Discovery Ltd. filed Critical Darwin Discovery Ltd.
Publication of HUP0100597A2 publication Critical patent/HUP0100597A2/hu
Publication of HUP0100597A3 publication Critical patent/HUP0100597A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány mátrix metalloproteinázok és/vagy TNFa-mediált betegségek,köztük degeneratív betegségek és bizonyos rákok inhibitoraikéntalkalmazható (I) általános képletű vegyületekre B-X- (CH2)m (CR1R2)n-W-COY (I) - amelyek képletében m 0, 1 vagy 2; n 1 vagy 2, azzal amegkötéssel, hogy ha m 0, akkor n 2; X S(O)0-2 csoport; Y hidrogénatom, hidroxi- vagy hidroxi-amino-csoport; W karbonil- vagy hidroxi-metilén-csoport, vagy ha Yhidrogénatom, W N-OR8 csoportot is jelenthet; R1 hidrogénatom, adottesetben R7 csoporttal szubsztituált alkil-, alkenil-, aril-, aril-(alkil)-, heteroaril-, heteroaril-(alkil)-, heterocikloalkil-,heterocikloalkil-(alkil)-, cikloalkil- vagy cikloalkil-(alkil)-csoport; és R2 hidrogénatom vagy alkilcsoport, azzal a megkötéssel,hogy a -(CR1R2)n- csoport -(CH2)n- csoporttól eltérő; vagy CR1R2 adottesetben szubsztituált cikloalkilcsoport vagy heterocikloalkilcsoport;B adott esetben szubsztituált aril-(alkil)-, alkil-, cikloalkil-,cikloalkil-(alkil)-, cikloalkenil-, heterocikloalkenil-, heteroaril-(alkil)-, heterocikloalkil-, heterocikloalkil-(alkil)-, aril- vagyheteroarilcsoport; R3 alkilcsoport, halogénatom, ciano-, nitrocsoport,-N(R4)2, -OR4, -COR4, -C(=NOR6)R4, -CO2R8, -CON(R4)2, -NR4R5, -S(O)0-2R6 vagy -SO2N(R4)2 csoport; R4 hidrogénatom, adott esetbenszubsztituált alkil-, aril-, aril--(alkil)-, heteroaril-, heteroaril-(alkil)-, cikloalkil-, cikloalkil-(alkil)-, heterocikloalkil- vagyhetrocikloalkil-(alkil)-csoport; R5 -COR4, -CON(R4)2, -C02R6 vagy -SO2R6 csoport; R6 alkil-, aril-,aril-(alkil)-, heteroaril- vagy heteroaril-(alkil)--csoport; R7 -OR4, -COR4, -CO2R8, -CON(R4)2, -NR4R5, -S(O)0-2R6, -SO2N(R4)2csoport, halogénatom, cianocsoport vagy adott esetben R8 csoporttalszubsztituált cikloimidilcsoport; és R8 hidrogénatom vagy alkilcsoport- valamint sóikra, szolvátjaikra, hidrátjaikra, N-oxidjaikra, védettamino-, védett karboxi- és védett hidroxi-amino-származékaikravonatkozik. Ó
HU0100597A 1998-01-30 1999-01-29 Hydroxamic and carboxylic acid derivatives HUP0100597A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9802073.8A GB9802073D0 (en) 1998-01-30 1998-01-30 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
GBGB9819574.6A GB9819574D0 (en) 1998-09-08 1998-09-08 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US09/239,603 US6100266A (en) 1998-01-30 1999-01-29 Hydroxamic and carboxylic acid derivatives
PCT/GB1999/000313 WO1999038843A1 (en) 1998-01-30 1999-01-29 Hydroxamic and carboxylic acid derivatives

Publications (2)

Publication Number Publication Date
HUP0100597A2 true HUP0100597A2 (hu) 2001-08-28
HUP0100597A3 HUP0100597A3 (en) 2001-12-28

Family

ID=27269200

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100597A HUP0100597A3 (en) 1998-01-30 1999-01-29 Hydroxamic and carboxylic acid derivatives

Country Status (18)

Country Link
US (1) US6100266A (hu)
EP (1) EP1051395B1 (hu)
JP (1) JP2002501943A (hu)
CN (1) CN100402496C (hu)
AT (1) ATE346041T1 (hu)
AU (1) AU735929B2 (hu)
BR (1) BR9908215A (hu)
CA (1) CA2317455C (hu)
CY (1) CY1106338T1 (hu)
DE (1) DE69934094T2 (hu)
DK (1) DK1051395T3 (hu)
ES (1) ES2277424T3 (hu)
HK (1) HK1029330A1 (hu)
HU (1) HUP0100597A3 (hu)
IL (1) IL137146A0 (hu)
NO (1) NO326266B1 (hu)
PL (1) PL200418B1 (hu)
WO (1) WO1999038843A1 (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
CA2374460A1 (en) 1999-06-04 2000-12-14 Astrazeneca Ab Inhibitors of metalloproteinases
JP2003519119A (ja) * 1999-12-24 2003-06-17 スミスクライン ビーチャム パブリック リミテッド カンパニー （ヘテロ）ビシクリルメタンスルホニルアミノ置換ヒドロキサム酸誘導体
JP4256095B2 (ja) * 2000-02-21 2009-04-22 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼの阻害剤としてのピペリジン−およびピペラジン置換ｎ−ヒドロキシホルムアミド類
WO2001062750A1 (en) * 2000-02-21 2001-08-30 Astrazeneca Ab Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
IL152990A0 (en) * 2000-05-25 2003-06-24 Smithkline Beecham Plc Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides
FR2827859B1 (fr) * 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
GB0119474D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
GB0119473D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Compounds
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
ES2319970T3 (es) 2001-09-07 2009-05-18 Kaken Pharmaceutical Co., Ltd. Derivados de acido hidroxamico inverso.
GB0128376D0 (en) * 2001-11-27 2002-01-16 Smithkline Beecham Plc Novel compounds
GB0128378D0 (en) * 2001-11-27 2002-01-16 Smithkline Beecham Plc Novel Compounds
SE0301922D0 (sv) 2003-06-27 2003-06-27 Astrazeneca Ab Novel compounds
WO2007060132A1 (en) * 2005-11-24 2007-05-31 Laboratoires Serono S.A. N-hydroxyamide derivatives and use thereof
US20100226922A1 (en) * 2006-06-08 2010-09-09 Dorothea Maetzel Specific protease inhibitors and their use in cancer therapy
US8765814B2 (en) * 2010-07-08 2014-07-01 Kaken Pharmaceutical Co., Ltd. N-hydroxyformamide derivative and medicament containing same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4267293A (en) * 1992-05-01 1993-11-29 British Biotech Pharmaceuticals Limited Use of MMP inhibitors
EP0826000B1 (en) * 1995-05-10 2002-10-23 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
EP0994104A4 (en) * 1996-06-27 2001-09-12 Ono Pharmaceutical Co ARYL SULFIDE, SULFOXIDE AND SULPHONE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM AS AN ACTIVE INGREDIENT
UA48262C2 (uk) * 1996-09-27 2002-08-15 Фармація Енд Апджон Компані <font face="Symbol">b</font>-СУЛЬФОНІЛ ГІДРОКСАМОВІ КИСЛОТИ ЯК ІНГІБІТОРИ МАТРИЧНИХ МЕТАЛОПРОТЕЇНАЗ, ПРОМІЖНА СПОЛУКА ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ
US5962481A (en) * 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6476027B1 (en) * 1997-03-04 2002-11-05 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
CN1178906C (zh) * 1997-07-31 2004-12-08 艾博特公司 基质金属蛋白酶的逆异羟肟酸盐抑制剂

Also Published As

Publication number Publication date
NO326266B1 (no) 2008-10-27
CY1106338T1 (el) 2011-10-12
CA2317455A1 (en) 1999-08-05
BR9908215A (pt) 2000-11-28
AU2291499A (en) 1999-08-16
ES2277424T3 (es) 2007-07-01
NO20003868D0 (no) 2000-07-28
DE69934094D1 (de) 2007-01-04
CN100402496C (zh) 2008-07-16
CA2317455C (en) 2011-01-25
IL137146A0 (en) 2001-07-24
NO20003868L (no) 2000-07-28
CN1289322A (zh) 2001-03-28
ATE346041T1 (de) 2006-12-15
WO1999038843A1 (en) 1999-08-05
EP1051395A1 (en) 2000-11-15
HUP0100597A3 (en) 2001-12-28
PL200418B1 (pl) 2009-01-30
JP2002501943A (ja) 2002-01-22
DK1051395T3 (da) 2007-04-02
PL342184A1 (en) 2001-05-21
DE69934094T2 (de) 2007-06-06
US6100266A (en) 2000-08-08
AU735929B2 (en) 2001-07-19
HK1029330A1 (en) 2001-03-30
EP1051395B1 (en) 2006-11-22

Similar Documents

Publication Publication Date Title
HUP0100597A2 (hu) Hidroxámsav- és karbonsavszármazékok
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
BRPI0414792A (pt) derivados de ácido 4-(1h-indol-3-il-metilidenoaminóxi-propóxi)-benzóico e compostos relacionados como inibidores de pai-1 para o tratamento de enfraquecimento do sistema fibrinolìtico e de trombose
ATE234299T1 (de) Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
BR0210504A (pt) Derivados de naftil-indol substituidos, atuantes como inibidores do inibidor tipo 1 (pai-1) do ativador de plasminogênio
BR0316583A (pt) Derivados de ácido acético 3-alquil e 3-arilalquil 1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
NO331013B1 (no) Nye forbindelser som er anti-inflammasjons, immunomodulerende og anti-proliferative midler, anvendelse av forbindelsene samt farmasoytisk preparat
DE60304059D1 (de) 3-(2-hydroxy-phenyl)-1h-pyrazol-4-carbonsäureamid derivate als hsp90 inhibitoren zur behandlung von krebs
BRPI0610312B8 (pt) dispositivo de assistência à caminhada
DE60330150D1 (en) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
DE60226469D1 (de) Biphenylkarbonsäureamidderivate als p38 kinase-inhibitoren
DE60027420D1 (de) Tri-aryl-säurederivate als ppar rezeptor liganden
NO20005463L (no) Nye fettsyreanaloger for behandling av primær og sekundær restenose
BR9910119A (pt) Derivados heterocìclicos de glicil beta-alanina como antagonistas de vitronectina
CY1110969T1 (el) 5-υποκατεστημενα-2-φαινυλαμινο-βενζαμιδια ως αναστολεiς μεκ
TR200003094T2 (tr) Glukokortikoid-seçimli enflamasyon önleyici maddeler.
MXPA05009535A (es) Compuestos de acido n - alquil - hidroxamico - isoindolilo y sus usos farmaceuticos.
AU3599701A (en) Fluorescent probes for the quantitation of zinc
ATE252576T1 (de) Heteroarylphenylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
DE69905476T2 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
HUP0100865A2 (hu) Meta-azaciklusos csoporttal N-szubsztituált amino-benzoesav-vegyületek és származékaik mint integrin antagonista hatóanyagok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE332903T1 (de) Kondensierte pyridoindolderivate
ATE342261T1 (de) Pyranderivate als inhibitoren von ace und nep
BR9305991A (pt) Derivados de indol como inibidores da esteróide 5 alfa redutase
NO20051028L (no) Substituerte tiaziner som materialbeskyttelsesmidler

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished